Last updated: September 1, 2026
Pomalidomide, marketed by Bristol Myers Squibb as Pomalyst in the United States and Imnovid in many international markets, remains a commercially important multiple myeloma product despite declining exclusivity. Global sales reached roughly $3.5 billion in 2023 and remained near that level in 2024, supported by combination use in relapsed or refractory disease. The product faces medium-term erosion from generic entry, but its market decline is likely to be gradual because pomalidomide is embedded in several established treatment regimens and has limited direct substitution in later-line disease.
What is pomalidomide and which company markets it?
Pomalidomide is an oral immunomodulatory drug, or IMiD, structurally related to thalidomide and lenalidomide. Bristol Myers Squibb owns and markets the product following its acquisition of Celgene in 2019.
| Product |
Active ingredient |
Principal company |
Main market |
| Pomalyst |
Pomalidomide |
Bristol Myers Squibb |
United States |
| Imnovid |
Pomalidomide |
Bristol Myers Squibb |
Europe and other international markets |
The principal approved use is treatment of multiple myeloma in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease has progressed on or after the last therapy. The product is administered with dexamethasone and is also used in combination regimens with agents such as daratumumab, bortezomib, and isatuximab.[1]
The FDA approved Pomalyst in February 2013 under the accelerated approval pathway. A supplemental indication for adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy was approved in 2020.[2]
How large is the pomalidomide market?
Pomalidomide generates approximately $3.4 billion to $3.5 billion in annual global revenue for Bristol Myers Squibb. Sales are concentrated in the United States, where pricing is substantially higher than in many international markets.
| Fiscal year |
Pomalyst/Imnovid revenue |
Year-over-year change |
| 2021 |
$3.014 billion |
|
| 2022 |
$3.274 billion |
8.6% |
| 2023 |
$3.519 billion |
7.5% |
| 2024 |
Approximately $3.4 billion |
Low-single-digit decline |
Sources: Bristol Myers Squibb annual reports and product-sales disclosures.[3,4]
The revenue pattern differs from the trajectory of Revlimid, Celgene’s former flagship IMiD. Revlimid entered significant generic erosion in the United States after negotiated launch arrangements with multiple generic manufacturers. Pomalyst has remained more stable because:
- It is used later in the multiple myeloma treatment sequence.
- There are fewer commercially interchangeable oral IMiD options for patients who have progressed on lenalidomide.
- Combination regimens preserve demand even as physicians shift toward antibody therapies and cellular therapies.
- Generic entry has been constrained by patent litigation and risk-management requirements.
- The product has a substantial installed base among hematologists familiar with its dosing and safety-monitoring system.
What is driving pomalidomide demand?
Relapsed and refractory multiple myeloma
The core market is relapsed or refractory multiple myeloma. Pomalidomide is frequently prescribed after lenalidomide resistance, where continued use of lenalidomide is clinically unattractive. Its principal commercial role is as a backbone drug in multi-agent treatment.
Important combinations include:
| Regimen |
Components |
Commercial relevance |
| Pd |
Pomalidomide plus dexamethasone |
Foundational later-line regimen |
| DPd |
Daratumumab, pomalidomide, dexamethasone |
Expands pomalidomide use in antibody-based therapy |
| PVd |
Pomalidomide, bortezomib, dexamethasone |
Important option after prior lenalidomide exposure |
| Isa-Pd |
Isatuximab, pomalidomide, dexamethasone |
Supports continued use in relapsed disease |
The product benefits from the treatment pattern in which patients receive multiple sequential therapies over the course of their disease. However, average duration of therapy can fall as physicians move eligible patients to bispecific antibodies, CAR-T therapies, or other intensive approaches.
Growth in the treated multiple myeloma population
Multiple myeloma prevalence continues to increase because of improved survival and expanded treatment options. That trend supports the overall demand pool for pomalidomide. The offset is that pomalidomide is generally used after several prior lines of therapy, and newer products increasingly compete for those same patients.
The highest-value commercial segment is the United States, followed by Europe and Japan. Pricing and reimbursement restrictions produce lower net sales per patient in many international markets.
When does pomalidomide lose exclusivity?
Pomalidomide’s regulatory exclusivity has expired, while its commercial protection depends on remaining patents, patent settlements, and the timing of FDA-approved generic launches.
| Protection type |
Relevant timing |
| FDA approval |
February 2013 |
| New chemical entity exclusivity |
Expired in 2018 |
| Orphan-drug exclusivity for the original multiple myeloma indication |
Expired in 2020 |
| Core composition-patent protection |
Expired or substantially exhausted before the current formulation and method-of-use barriers |
| Key later-issued patent protection |
Extends into the late 2020s, with some claims potentially reaching the early 2030s |
| Generic risk |
Material before the end of the decade, subject to litigation and settlements |
The exact generic-entry date is controlled by the enforceable patent claims, any 180-day first-filer exclusivity, and settlement terms between Bristol Myers Squibb and individual ANDA applicants. Public patent records should be read together with the FDA Orange Book and district-court dockets rather than relying on a single expiration date.[5,6]
What patents protect Pomalyst?
The patent estate is layered. It includes the active pharmaceutical ingredient, formulations, methods of treatment, dosing schedules, and regulatory-use restrictions.
Core composition patents
Early pomalidomide patents covered the chemical compound and related thalidomide analogs. Those rights provided the original exclusivity platform but are no longer the primary commercial barrier.
Formulation patents
Formulation protection can cover capsule compositions, dosage strengths, excipients, dissolution characteristics, and pharmaceutical presentations. Formulation patents are relevant because an ANDA applicant must show pharmaceutical equivalence and may need to address listed patents even when the active ingredient itself is no longer protected.
Method-of-use patents
Later patents cover treatment of multiple myeloma, particular patient populations, combination therapy, and dosing schedules. These patents can support a so-called skinny-label strategy if a generic applicant omits patented indications from its label. Their practical value depends on physician prescribing behavior and the ability to prove induced or contributory infringement.
REMS and distribution controls
Pomalyst is distributed through a restricted program because of teratogenicity risks. The Pomalyst Risk Evaluation and Mitigation Strategy requires prescriber, pharmacy, and patient controls, including pregnancy testing and contraception requirements where applicable.[7]
The REMS does not create patent exclusivity. It can, however, raise operational barriers for manufacturers entering the market and must be addressed through FDA-compliant distribution systems.
What is the Orange Book status of Pomalyst?
Pomalyst has Orange Book-listed patents associated with the product’s active ingredient, formulation, and approved uses. The Orange Book is the controlling FDA reference for patents submitted by the NDA holder, but it does not determine whether every listed claim will survive litigation.
The commercial significance of an Orange Book listing depends on the ANDA applicant’s certification:
- Paragraph I: No relevant patent information is listed.
- Paragraph II: The listed patent has expired.
- Paragraph III: The applicant will wait until the listed patent expires.
- Paragraph IV: The applicant asserts that the patent is invalid, unenforceable, or will not be infringed.
A Paragraph IV filing can trigger a 30-month stay of FDA approval if Bristol Myers Squibb brings an infringement action within the statutory period.[8]
Which companies are challenging pomalidomide patents?
Generic drug manufacturers have pursued abbreviated new drug applications for pomalidomide capsules. The relevant competitive group has included major Indian, U.S., and multinational generic manufacturers, including firms such as Teva, Dr. Reddy’s Laboratories, Natco, Zydus, and other ANDA applicants.
The litigation structure is fragmented. Different manufacturers may challenge different Orange Book patents, and settlement terms may permit launches on different dates. A first-filer may also obtain 180-day exclusivity, delaying broader generic competition.
Publicly disclosed settlements in branded pharmaceutical litigation often establish an agreed launch date without making all economic terms public. As a result, the presence of a settlement does not necessarily mean immediate generic availability.
What generic entry risks exist for pomalidomide?
The risk is best characterized as staged rather than abrupt.
Scenario 1: Delayed single-generic entry
One generic manufacturer launches under a settlement or after prevailing in litigation. Bristol Myers Squibb retains a portion of the market through brand loyalty, supply reliability, and physician familiarity. Net price declines, but revenue erosion is gradual.
Scenario 2: Multiple-generic entry
Several manufacturers launch after patent barriers fall. Pomalidomide then follows the standard oral-solid-dose generic pattern, with rapid price compression and loss of market share. This is the most severe revenue-risk scenario.
Scenario 3: Limited skinny-label competition
Generic products initially exclude selected method-of-use indications. Competition is narrower, particularly if branded use remains concentrated in patented combinations or restricted patient populations.
The likely commercial sequence is a moderate decline before full generic competition, followed by materially faster erosion when multiple suppliers enter. The U.S. market is the primary exposure because it contributes the largest revenue per treated patient.
How does pomalidomide compare with Revlimid?
| Factor |
Pomalidomide |
Revlimid |
| Active ingredient |
Pomalidomide |
Lenalidomide |
| Commercial position |
Later-line multiple myeloma |
Broad multiple myeloma and hematology franchise |
| Original FDA approval |
2013 |
2005 |
| Generic exposure |
Emerging later-decade risk |
Established U.S. generic erosion |
| Main clinical role |
After lenalidomide exposure or resistance |
Earlier and broader treatment use |
| Revenue sensitivity |
Dependent on later-line patient volume |
Highly exposed to generic launches |
| Differentiation |
Retains utility after lenalidomide failure |
Larger indication breadth |
Pomalidomide has a smaller but more defensible niche than Revlimid. Its role after lenalidomide failure reduces direct substitution by lenalidomide, but new therapies increasingly compete for the same later-line patients.
How does pomalidomide compare with newer myeloma therapies?
Pomalidomide competes with several classes:
- Anti-CD38 antibodies, including daratumumab and isatuximab.
- Proteasome inhibitors, including carfilzomib and newer agents.
- BCMA-directed CAR-T therapies.
- BCMA-directed bispecific antibodies.
- Selinexor and other oral salvage therapies.
- Clinical-trial agents used in triple-class-exposed disease.
Pomalidomide remains advantageous where physicians need an oral backbone drug with established combination data and manageable logistics. CAR-T and bispecific therapies may displace pomalidomide in patients who qualify for advanced immunotherapies, but those products have higher administration complexity, capacity limits, and reimbursement constraints.
The competitive threat is therefore strongest in patients with aggressive disease, treatment resistance across several classes, or access to specialized centers. Pomalidomide remains more resilient in routine outpatient combination therapy.
What is the FDA regulatory status of pomalidomide?
Pomalyst is FDA approved for multiple myeloma after at least two prior therapies, including lenalidomide and a proteasome inhibitor, and for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy.[1,2]
The principal regulatory constraints are:
- Teratogenicity controls.
- Blood-count monitoring.
- Thromboembolic risk management.
- Restricted prescribing and dispensing.
- Generic manufacturer compliance with equivalent risk controls.
There is no biosimilar pathway for pomalidomide because it is a chemically synthesized small molecule. Competition will arise through the ANDA pathway, not through biosimilar applications.
How strong is the pomalidomide patent estate?
The estate is moderate rather than exceptionally strong.
Its strengths are the layered protection around formulation, dosing, and methods of treatment; the operational complexity of the REMS; and the clinical dependence of many regimens on an oral IMiD backbone.
Its weaknesses are the age of the active ingredient, expiration of the earliest exclusivity rights, the availability of alternative formulations and manufacturing routes, and the likelihood that multiple generic companies will challenge later-issued patents.
The highest-value claims are those that protect commercially unavoidable uses or dosage forms. Narrow method-of-use claims are less durable if generic applicants can omit the covered indication and physicians prescribe outside the patented label.
What is the financial trajectory for pomalidomide?
Pomalidomide has entered the mature-growth phase of its product lifecycle.
| Period |
Financial interpretation |
| 2013-2018 |
Rapid uptake after FDA approval and expansion of the relapsed myeloma market |
| 2019-2021 |
Continued growth supported by Celgene/Bristol Myers Squibb commercialization and combination use |
| 2022-2024 |
High revenue plateau near $3.3 billion to $3.5 billion |
| Late 2020s |
Expected decline as generic entry expands and new myeloma therapies take share |
| Post-generic maturity |
Revenue likely becomes a fraction of branded peak, with residual demand from combination regimens and international markets |
Pomalidomide is strategically important to Bristol Myers Squibb because it generates substantial cash flow without requiring the development cost of a new molecular entity. Its value is declining at the portfolio level as newer products such as Abecma, Breyanzi, Opdualag, and other growth assets receive greater strategic emphasis.
Revenue exposure is concentrated in the U.S. patent and litigation outcome. A delayed generic launch would preserve several billion dollars of annualized sales for longer. An early multi-generic launch would produce a sharper decline in both volume and net price.
What licensing deals affect pomalidomide?
The principal ownership and commercialization transaction is Bristol Myers Squibb’s acquisition of Celgene, completed in 2019. That transaction transferred Celgene’s pomalidomide business, intellectual property, regulatory rights, and commercial infrastructure to Bristol Myers Squibb.[9]
Pomalidomide is also subject to distribution and supply arrangements typical of a restricted oral oncology product. No separate licensing transaction has become as commercially important as the Celgene acquisition.
What patent litigation affects Pomalyst?
Pomalyst litigation centers on Paragraph IV ANDA filings and challenges to Orange Book-listed patents. The cases generally involve:
- Invalidity challenges based on obviousness.
- Non-infringement arguments directed to formulation or method claims.
- Patent-term and expiration disputes.
- Settlement negotiations over generic launch dates.
- The impact of 180-day first-filer exclusivity.
The legal outcome matters less than the earliest enforceable commercial launch date. A favorable validity decision can preserve the market until patent expiration, while a successful generic challenge can accelerate entry by several years.
Key Takeaways
- Pomalidomide generated about $3.4 billion to $3.5 billion in annual global sales during 2023-2024.
- Bristol Myers Squibb owns the product through its acquisition of Celgene.
- The core market is relapsed or refractory multiple myeloma after lenalidomide and proteasome-inhibitor exposure.
- Demand remains supported by Pd, DPd, PVd, and Isa-Pd combination regimens.
- FDA regulatory exclusivity has expired, but later-issued patents and litigation continue to influence generic timing.
- Pomalidomide has no biosimilar risk. Future competition will come through ANDA-approved generics.
- The product’s patent estate is layered but vulnerable to Paragraph IV challenges and skinny-label strategies.
- Revenue should remain resilient until generic entry, then decline faster if several manufacturers launch in close succession.
- The primary financial variables are U.S. patent settlements, first-filer exclusivity, and the speed of adoption of CAR-T and bispecific therapies.
FAQs
Is pomalidomide still commercially important after Revlimid generic entry?
Yes. Pomalidomide is used after lenalidomide failure and remains a key oral component of later-line myeloma combinations.
Does pomalidomide have biosimilar competition?
No. Pomalidomide is a small-molecule drug and is subject to the FDA ANDA generic pathway rather than the biosimilar pathway.
Can generic pomalidomide be sold through ordinary retail pharmacies?
Generic manufacturers must meet FDA requirements for the applicable restricted-distribution and risk-management system. Commercial distribution is not identical to an unrestricted generic capsule.
Which products most directly threaten pomalidomide sales?
Daratumumab- and isatuximab-based combinations, BCMA-directed CAR-T therapies, bispecific antibodies, carfilzomib combinations, and other later-line treatments are the principal competitive threats.
What would cause the fastest decline in pomalidomide revenue?
The fastest decline would follow an early successful patent challenge or coordinated entry by multiple generic manufacturers after expiration or settlement-based launch dates.
References
- U.S. Food and Drug Administration. (2024). Pomalyst (pomalidomide) prescribing information.
- U.S. Food and Drug Administration. (2020). FDA approves pomalidomide for AIDS-related Kaposi sarcoma.
- Bristol Myers Squibb. (2023). 2023 annual report.
- Bristol Myers Squibb. (2024). 2024 annual report.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information.
- U.S. Food and Drug Administration. (2024). Pomalyst Risk Evaluation and Mitigation Strategy.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
- Bristol Myers Squibb. (2019). Bristol-Myers Squibb completes acquisition of Celgene.
